Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073203 · ClinicalTrials.gov registry record · Phase 2
A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder
A Phase 2 study of Major Depressive Disorder, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 488
- Enrollment target
- 1
- Study location
NCT00073203 is a Phase 2 study of Major Depressive Disorder that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 488 participants, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (30% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00073203, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 488 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine the effectiveness of 2 target doses of R228060 in comparison with placebo during 6 weeks of treatment in moderately to severely depressed adult subjects with major depressive disorder. Approximately 488 subjects will be involved in the study.
Conditions Studied
Interventions
- DRUG R228060
- DRUG Placebo and Paroxetine
Study Locations (1)
New Jersey
- JJ PRD Research Center - Titusville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 488 participants |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073203
The ClinicalTrials.gov registry entry for NCT00073203 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 488 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (30% higher). The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which R228060 is the first listed.
NCT00073203 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00073203 about?
NCT00073203 is a clinical study titled "A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder". The purpose of this research study is to determine the effectiveness of 2 target doses of R228060 in comparison with placebo during 6 weeks of treatment in moderately to severely depressed adult subjects with major depressive disorder. Approximately 488 subjects will be involved in the study.
What is the current status of trial NCT00073203?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 488 participants. Estimated completion is 2004-05.
What conditions does trial NCT00073203 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00073203?
The interventions under investigation include: R228060 (DRUG), Placebo and Paroxetine (DRUG).
Who is sponsoring clinical trial NCT00073203?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00073203 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.